Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment

被引:0
|
作者
Agnes V Tallet
David Azria
Fabrice Barlesi
Jean-Philippe Spano
Antoine F Carpentier
Antony Gonçalves
Philippe Metellus
机构
[1] Institut Paoli Calmettes,Department of Radiation Oncology
[2] CRLC Val d'Aurelle,Department of Radiation Oncology and INSERM U896
[3] Centre Investigation Clinique,Multidisciplinary Oncology and Therapeutic Innovations Department &
[4] Aix Marseille University -Assistance Publique Hôpitaux de Marseille,Department of Medical Oncology, GH Pitié
[5] Université Paris 6,Salpêtrière
[6] Assistance Publique des Hopitaux de Paris,Department of Neurology, Hopital Avicenne
[7] Aix-Marseille University,Department of Medical Oncology, Institut Paoli Calmettes, Centre de Recherche en Cancérologie de Marseille UMR1068 INSERM
[8] Hopital La Timone,Department of Neurosurgery
[9] Assistance Publique-Hôpitaux de Marseille and INSERM UMR 911,undefined
[10] Groupe de Réflexion sur la Prise en Charge des MétAstases Cérébrales GRPCMaC,undefined
来源
关键词
Neurocognitive impairment; Whole brain radiation therapy; Brain metastases;
D O I
暂无
中图分类号
学科分类号
摘要
Whole brain radiation therapy (WBRT) is an effective treatment in brain metastases and, when combined with local treatments such as surgery and stereotactic radiosurgery, gives the best brain control. Nonetheless, WBRT is often omitted after local treatment due to its potential late neurocognitive effects. Publications on radiation-induced neurotoxicity have used different assessment methods, time to assessment, and definition of impairment, thus making it difficult to accurately assess the rate and magnitude of the neurocognitive decline that can be expected. In this context, and to help therapeutic decision making, we have conducted this literature review, with the aim of providing an average incidence, magnitude and time to occurrence of radio-induced neurocognitive decline. We reviewed all English language published articles on neurocognitive effects of WBRT for newly diagnosed brain metastases or with a preventive goal in adult patients, with any methodology (MMSE, battery of neurcognitive tests) with which baseline status was provided. We concluded that neurocognitive decline is predominant at 4 months, strongly dependant on brain metastases control, partially solved at later time, graded 1 on a SOMA-LENT scale (only 8% of grade 2 and more), insufficiently assessed in long-term survivors, thus justifying all efforts to reduce it through irradiation modulation.
引用
收藏
相关论文
共 50 条
  • [1] Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment
    Tallet, Agnes V.
    Azria, David
    Barlesi, Fabrice
    Spano, Jean-Philippe
    Carpentier, Antoine F.
    Goncalves, Antony
    Metellus, Philippe
    RADIATION ONCOLOGY, 2012, 7
  • [2] Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy
    Salzmann, Martin
    Hess, Klaus
    Lang, Kristin
    Enk, Alexander H.
    Jordan, Berit
    Hassel, Jessica C.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (10) : 884 - 891
  • [3] Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy
    Martin Salzmann
    Klaus Hess
    Kristin Lang
    Alexander H. Enk
    Berit Jordan
    Jessica C. Hassel
    Strahlentherapie und Onkologie, 2022, 198 : 884 - 891
  • [4] Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy
    Salzmann, M.
    Hess, K.
    Lang, K.
    Enk, A.
    Jordan, B.
    Hassel, J. C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 16 - 16
  • [5] MEMORY FUNCTION BEFORE AND AFTER WHOLE BRAIN RADIOTHERAPY IN PATIENTS WITH AND WITHOUT BRAIN METASTASES
    Welzel, Grit
    Fleckenstein, Katharina
    Schaefer, Joerg
    Hermann, Brigitte
    Kraus-Tiefenbacher, Uta
    Mai, Sabine K.
    Wenz, Frederik
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (05): : 1311 - 1318
  • [6] Concomitant treatment of brain metastases with whole brain radiotherapy and temozolomide protects neurocognitive function and improve quality of life
    Zhan, Yufei
    Jiang, Xiaodan
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2018, 17 (06) : 1209 - 1213
  • [7] Whole brain radiotherapy for brain metastases
    Brown, Paul D.
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 355
  • [8] Whole-brain radiotherapy improves neurocognitive function of patients with brain metastasis
    Adamietz, Irenaeus A.
    Milanovic, Dusan
    STRAHLENTHERAPIE UND ONKOLOGIE, 2008, 184 (10) : 544 - 545
  • [9] EVOLUTION OF NEUROCOGNITIVE FUNCTIONING AFTER RADIOTHERAPY IN PATIENTS WITH BRAIN METASTASES
    van Grinsven, E. E.
    Meijling, Y. A. Gmelich
    Cialdella, F.
    Verhoeff, J. J. C.
    Philippens, M. E. P.
    van Zandvoort, M. J. E.
    NEURO-ONCOLOGY, 2023, 25
  • [10] Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function
    Li, Jing
    Bentzen, Soren M.
    Renschler, Markus
    Mehta, Minesh P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (10) : 1260 - 1266